Evidence map›Paper›PMID 29713954›Full record

Trial reportInternational journal of hematology2018

Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.

Shinsuke Noguchi, Chiaki Nakaseko, Kaichi Nishiwaki, Hitoshi Ogasawara, Kohshi Ohishi, Michihide Tokuhira, Masaaki Noguchi, Hideo Kimura, Hiroshi Handa, Kinuko Mitani and 4 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Shinsuke NoguchiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Chiaki NakasekoDepartment of Hematology, International University of Health and Welfare School of Medicine, Narita, Japan.
Kaichi NishiwakiDepartment of Oncology and Hematology, Jikei University Kashiwa Hospital, Kashiwa, Japan.
Hitoshi OgasawaraDepartment of Hematology and Oncology, Odate Municipal Hospital, Odate, Japan.
Kohshi OhishiDepartment of Transfusion Service, Mie University Hospital, Tsu, Japan.
Michihide TokuhiraDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan.
Hideo KimuraDepartment of Hematology, Northern Fukushima Medical Center, Date, Japan.
Hiroshi HandaDepartment of Hematology, Gunma University Hospital, Maebashi, Japan.
Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, Mibu-machi, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, Akita, Japan.
Hisashi WakitaDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. naotot@doc.med.akita-u.ac.jp.ORCID http://orcid.org/0000-0002-6758-3787
STAT study group
Akita University · JPAkita University Hospital · JPMie University Hospital · JPTokyo Metropolitan Tama-Hokubu Medical Center · JPChiba University Hospital · JPGunma University Hospital · JPJuntendo University Urayasu Hospital · JPOdawara Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this clinical trial was to evaluate the efficacy of 2-year consolidation therapy using nilotinib (NIL) for achieving a molecular response (MR

Indexed as

Drug SubstitutionAdultAgedAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2Consolidation ChemotherapyFemaleFusion Proteins, bcr-ablHumansImatinib MesylateJapanLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNeoplasm ProteinsPyrimidinesABCG2 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2BCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablImatinib Mesylatemacrophage MHC receptor 1, humanNeoplasm ProteinsnilotinibPyrimidinesReceptors, ImmunologicABCG2Chronic myeloid leukemiaDeep molecular responseTyrosine kinase inhibitor

Identifiers

PMID29713954
OpenAlexW2799468555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.